NOVEL DKKL-1 Splice Product Modulators for Cancer Diagnosis and Therapy
AssigneeSagres Discovery, Inc.
InventorsAlbert Lai, Robert Booher
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel sequences for use in detection, diagnosis and treatment of diseases, including cancer. The invention provides novel splice products of human DKKL-1 gene. The present invention provides methods of using polynucleotides having the novel splice products of the human DKKL-1 sequences, their corresponding gene products and modulators of the DKKL-1 splice products for the detection, diagnosis, prevention and/or treatment of associated cancers.
Claims72
An isolated antibody that specifically binds an epitope of a DKKL-1 splice product.
A composition comprising a DKKL-1 splice product modulator and one or more pharmaceutically acceptable carriers, wherein the DKKL-1 splice product modulator is an isolated double-stranded RNA (dsRNA) of SEQ ID NO:3 or SEQ ID NO:5;
- an isolated oligonucleotide comprising at least 10 consecutive nucleotides of a sequence of SEQ ID NO:3 or SEQ ID NO:5;
- or an antibody that specifically binds an epitope of a DKKL-1 splice product.
The method of claim 42 wherein the DKKL-1 splice product is DKKL-1 isoform 2 or DKKL-1 isoform 3.
A method of identifying a cancer inhibitor wherein the cancer is characterized by overexpression of a DKKL-1 splice product compared to a control, said method comprising contacting a cell expressing a DKKL-1 splice product with a candidate compound, and determining whether a downstream marker of a DKKL-1 splice product is inhibited, wherein inhibition of the downstream marker is indicative of a cancer inhibitor.
A method for screening for a DKKL-1 splice product modulator comprising contacting a cell expressing a DKKL-1 splice product with a test compound and measuring an activity of a member of a Wnt pathway, wherein if the activity of the member of the Wnt pathway is modulated compared to a control, then the test compound is a DKKL-1 splice product modulator.
A method for determining the susceptibility of a patient to a DKKL-1 splice product modulator comprising detecting evidence of differential expression of a DKKL-1 splice product in said patient's cancer sample, wherein evidence of differential expression of a DKKL-1 splice product is indicative of the patient's susceptibility to the DKKL-1 splice product modulator.
A method for determining the prognosis of a cancer patient comprising determining the ratio of wild-type DKKL-1 expression products to DKKL-1 splice product expression products in a sample of said patient, wherein the ratio of wild-type DKKL-1 expression products to DKKL-1 splice product expression products is used to determine the prognosis of the cancer patient.
Dependencies are inferred from the claim text.